Gebbia V, Testa A, Valenza R, Cipolla C, Amato C, Latteri M, Gebbia N, Florena M
Chair of Chemotherapy, Institute of Pharmacology.
Anticancer Res. 1993 Jan-Feb;13(1):141-4.
Twenty-two women affected by metastatic breast carcinoma have been treated with a combination of levo folinic acid 100 mg/m2 plus 5-fluorouracil 450 mg/m2 i.v. on day 1-2, and epidoxorubicin 75-90 mg/m2 on day 2. This treatment cycle was repeated every 21-28 days. No patients had previously received chemotherapy for metastatic disease. Fourteen patients (64%) showed a major objective response with 3 complete (14%) and 11 partial responses (50%). Three patients showed a stabilization of disease and 5 (23%) progressed. All patients received ondansetron as antiemetic treatment which led to complete protection from vomiting in 68% of cases. Grade 1-2 diarrhea was recorded in 27% of the patients. Ten patients received recombinant human granulocyte-colony stimulating factor (rhG-CSF) as leukopenia-preventive treatment. In this group of patients the interval between chemotherapeutic cycles was shorter than in the group of 12 patients who did not receive rhG-CSF.
22例转移性乳腺癌女性患者接受了如下联合治疗：第1 - 2天静脉注射左亚叶酸100 mg/m²加5-氟尿嘧啶450 mg/m²，第2天静脉注射表柔比星75 - 90 mg/m²。每21 - 28天重复此治疗周期。此前所有患者均未接受过针对转移性疾病的化疗。14例患者（64%）出现主要客观缓解，其中3例完全缓解（14%），11例部分缓解（50%）。3例患者疾病稳定，5例（23%）病情进展。所有患者均接受昂丹司琼作为止吐治疗，68%的患者呕吐得到完全控制。27%的患者出现1 - 2级腹泻。10例患者接受重组人粒细胞集落刺激因子（rhG-CSF）作为预防白细胞减少的治疗。在这组患者中，化疗周期之间的间隔比未接受rhG-CSF的12例患者组更短。
